Come up with a name for your new list and we'll add to it:
ImmuRx raised a round of funding on June 10, 2009. Investors include
Allyon Capital Partners.
ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immu…